THE Health Dept has published new fact sheets with information for pharmacists, prescribers and consumers in relation to the use of infliximab biosimilars, reflecting recent PBS listing changes.
PBS listings for infliximab (Remicade, Inflectra and Renflexis) are being amended as part of initiatives to encourage the use of biosimilar brands of biological medications, with changes phased over time for various indications including Severe Chronic Plaque Psoriasis, which was implemented on 01 Jan 2019 - see pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Feb 19